Pharmaron is a pharmaceutical R&D services platform that provides research, development, and manufacturing capabilities across the drug discovery, preclinical, and clinical development processes. The company organizes its services into four main categories: laboratory services, CMC (small molecule CDMO) services, clinical development services, and biologics and CGT services. It serves customers in North America, Europe, Japan, and China, with operations in China, the U.S., and the U.K. Founded in 2004, the group offers end-to-end solutions for small molecules, biologics, cell and gene therapies, ADCs, and protein degraders.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage pharmaron.com
Sector Healthcare IR page ir.pharmaron.com
Tags
contract research organization, cdmo, small molecules, biologics, cell and gene therapy, adc, protein degraders, clinical development, laboratory services, cmc, Pharmaron Holdings Limited
Press page pharmaron.com/about-us/latest-news

Metrics

Valuation  
Market cap HK$ 46.587B
Market cap (USD) $ 5.937B
P/E 24.99
PEG 3.80
P/BV 2.32
P/S 2.60
P/OCF 13.66
P/FCF —
Dividend yield 0.87%
Turnover / mcap 0.18%
Returns  
ROE 11.1%
ROI 8.1%
ROIC 8.1%
Profit margin 11.8%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 6.6%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 26.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 4
Quality score 17.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 14.095B 12.276B 11.538B 10.266B 7.444B 5.134B 3.757B 2.908B
Net profit 1.664B 1.793B 1.601B 1.375B 1.661B 1.172B 547.19M 336.042M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 17.42 25.39 14.55 59.41 138.48 91.91 39.34 —
Price performance 12m -0.3 0.76 -0.77 -0.59 0.62 1.35 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Pharmaron Beijing Co., Ltd. (ticker 3759), listed in Hong Kong.

ETFs Holding Pharmaron Beijing Co., Ltd.

ETF Weight in ETF Shares Market value As of
DFSE 0.02% 23,900 $ 90.973K Nov 12, 2026
DFEM 0.01% 343,475 $ 1.307M Nov 12, 2026
DFAE 0.01% 149,725 $ 569.916K Nov 12, 2026
DFAX 0.01% 185,925 $ 707.708K Nov 12, 2026
AVEM 0.00% 30,675 $ 109.148K Nov 16, 2026
AVSE 0.00% 375 $ 1,334.33 Nov 16, 2026